Adrian Woolfson, a former Pfizer Inc executive, has joined the Swiss vaccine company Nouscom AG as chief medical officer. In this role, he will manage the clinical development of the company’s neoantigen vaccines for cancer. At Pfizer, he oversaw clinical studies of the US company’s jointly developed checkpoint inhibitor avelumab. Prior to this, he was head of global clinical programmes at Bristol-Myers Squibb Co. Dr Woolfson received his clinical and post-graduate medical training at the University of Oxford and Addenbrooke’s Hospital in the UK. His PhD and post-doctoral studies were in the field of molecular immunology.
Nouscom announced the appointment on 29 May 2018.
Copyright 2018 Evernow Publishing Ltd